Abstract
BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.
| Original language | English |
|---|---|
| Pages (from-to) | 103-120 |
| Number of pages | 18 |
| Journal | Climacteric |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- Deficiency
- Estrogen
- Female sexual dysfunction
- Menopause
- Psychosocial
- Testosterone
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Therapeutic options for postmenopausal female sexual dysfunction. / Al-Azzawi, F.; Bitzer, J.; Brandenburg, U.; Castelo-Branco, C.; Graziottin, A.; Kenemans, P.; Lachowsky, M.; Mimoun, S.; Nappi, R. E.; Palacios, S.; Schwenkhagen, A.; Studd, J.; Wylie, K.; Zahradnik, H. P.
In: Climacteric, Vol. 13, No. 2, 04.2010, p. 103-120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic options for postmenopausal female sexual dysfunction
AU - Al-Azzawi, F.
AU - Bitzer, J.
AU - Brandenburg, U.
AU - Castelo-Branco, C.
AU - Graziottin, A.
AU - Kenemans, P.
AU - Lachowsky, M.
AU - Mimoun, S.
AU - Nappi, R. E.
AU - Palacios, S.
AU - Schwenkhagen, A.
AU - Studd, J.
AU - Wylie, K.
AU - Zahradnik, H. P.
PY - 2010/4
Y1 - 2010/4
N2 - BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.
AB - BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.
KW - Deficiency
KW - Estrogen
KW - Female sexual dysfunction
KW - Menopause
KW - Psychosocial
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=77249177134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77249177134&partnerID=8YFLogxK
U2 - 10.3109/13697130903437615
DO - 10.3109/13697130903437615
M3 - Article
C2 - 19958161
AN - SCOPUS:77249177134
VL - 13
SP - 103
EP - 120
JO - Climacteric
JF - Climacteric
SN - 1369-7137
IS - 2
ER -